Rituximab biosimilar (Samsung)

利妥昔单抗生物类似药（三星）

Report date: 2023/05/06 09:02:10

Base Information

Drug NameRituximab biosimilar (Samsung)
Drug Alias NameRituximab (Samsung)利妥昔单抗生物仿制药（三星）Rituximabum (Samsung)SAIT-101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmLymphoproliferative DisordersAnemia +[21] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBosnia and HerzegovinaBulgaria +[21] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesSamsung Biologics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesRutgers UniversityArchigen Biotech Ltd
Active IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmAnemiaHematologic Neoplasms +[13] 
Inactive IndicationsLymphoproliferative DisordersArthritis, RheumatoidLymphoma, T-Cell +[8] 

Other Information

ATC CodeL01XC02
Related LinksN/A